静脉丙种球蛋白联合抗生素治疗儿童难治性 肺炎支原体肺炎的疗效与安全性研究

Study on the Efficacy and Safety of Intravenous Gamma Globulin Combined with Antibiotics in the Treatment of Refractory Mycoplasma Pneumoniae Pneumonia in Children

摘要: 目的：探讨临床对儿童难治性肺炎支原体肺炎患儿采用静脉丙种球蛋白 + 抗生素完成治疗后获得的疗效以及安全性。方法：此次研究对我院2022年10月~2025年1月时间范围内的90例儿童难治性肺炎支原体肺炎患儿以分组的形式开展临床药物治疗工作；通过随机数字表法为依据划分为参照组(n = 45)、研究组(n = 45)共两个药物治疗小组；并分别予以注射用甲泼尼龙琥珀酸钠 + 大环内酯类抗生素、注射用甲泼尼龙琥珀酸钠 + 大环内酯类抗生素 + 静脉丙种球蛋白治疗；观察对比两组患儿的用药效果。结果：研究组患儿的临床用药结果与参照组的总有效率统计结果比较提升程度极为明显(P < 0.05)；研究组患儿的不良反应统计结果与参照组的总发生率统计结果比较未表现出显著差别(P > 0.05)；研究组治疗后的各项肺功能指标水平与参照组的测定结果比较均表现出显著提升(P < 0.05)；研究组治疗后的各项免疫细胞水平与参照组的测定结果比较均表现出显著改善(P < 0.05)；研究组治疗后的各项炎性因子水平与参照组的测定结果比较均表现出显著降低(P < 0.05)；研究组患儿的各项症状体征持续时间与参照组的统计结果比较后的缩短程度明显(P < 0.05)。结论：临床在研究儿童难治性肺炎支原体肺炎患儿的治疗方案期间，将静脉丙种球蛋白以及抗生素应用充分联合，可促进患儿的疗效提升，并且不会引起不良反应增加。

Abstract: Objective: To investigate the efficacy and safety of intravenous gamma globulin combined with antibiotics in the treatment of refractory Mycoplasma pneumoniae pneumonia (RMPP) in children. Methods: In this study, 90 children with RMPP admitted to our hospital between October 2022 and January 2025 were divided into two groups for clinical drug treatment based on a random number table method: a control group (n = 45) and a study group (n = 45). The control group received methylprednisolone sodium succinate for injection + macrolide antibiotics, while the study group received methylprednisolone sodium succinate for injection + macrolide antibiotics + intravenous gamma globulin. The medication effects were observed and compared between the two groups. Results: The total effective rate in the study group was significantly higher than that in the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the study group and the control group (P > 0.05). The levels of various pulmonary function indicators in the study group after treatment showed significant improvement compared to those in the control group (P < 0.05). The levels of various immune cells in the study group after treatment showed significant improvement compared to those in the control group (P < 0.05). The levels of various inflammatory factors in the study group after treatment showed a significant decrease compared to those in the control group (P < 0.05). The duration of various symptoms and signs in the study group was significantly shorter than that in the control group (P < 0.05). Conclusion: The combined application of intravenous gamma globulin and antibiotics in the clinical treatment of children with refractory Mycoplasma pneumoniae pneumonia can enhance therapeutic efficacy without increasing adverse reactions.